Evidence map›Paper›PMID 30774773›Full record

ArticleOncotarget2019

Prostate-specific loss of UXT promotes cancer progression.

Yu Wang, Eric D Schafler, Phillip A Thomas, Susan Ha, Gregory David, Emily Adney, Michael J Garabedian, Peng Lee, Susan K Logan

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yu WangDepartment of Urology, New York University School of Medicine, New York 10016, NY, USA.
Eric D SchaflerDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York 10016, NY, USA.
Phillip A ThomasDepartment of Urology, New York University School of Medicine, New York 10016, NY, USA.
Susan HaDepartment of Urology, New York University School of Medicine, New York 10016, NY, USA.
Gregory DavidDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York 10016, NY, USA.
Emily AdneyInstitute for Systems Genetics, New York University School of Medicine, New York 10016, NY, USA.
Michael J GarabedianDepartment of Urology, New York University School of Medicine, New York 10016, NY, USA.
Peng LeeDepartment of Urology, New York University School of Medicine, New York 10016, NY, USA.
Susan K LoganDepartment of Urology, New York University School of Medicine, New York 10016, NY, USA.
New York University · USJohns Hopkins Medicine · US

Funding

Transcription repression in prostate cancerR01CA112226 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOGAN, SUSAN K. · 2008 to 2019
$4.2M
Signaling Pathway Alterations in the Racial Disparity of Prostate CancerU01CA149556 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LEE, PENG, ZHANG, DAVID Y · 2011 to 2016
$1.9M
NCI NIH HHS R01 CA112226NCI NIH HHS U01 CA149556
6 · The paper itself

Abstract

Ubiquitously-expressed, prefoldin-like chaperone (UXT) also called Androgen Receptor Trapped clone-27 (ART-27) is widely expressed in human tissues. Our previous studies showed that UXT regulates transcription repression including androgen receptor (AR) signaling in prostate cancer. Here we analyzed a tissue microarray consisting of normal prostate, benign prostatic hyperplasia, high grade prostatic intraepithelial neoplasia (HGPIN) and primary prostate cancer cases for UXT protein expression. We found that HGPIN and malignant tumors have significantly decreased UXT expression compared to the normal prostate. Loss of UXT expression in primary prostate cancer is positively associated with high Gleason grade and poor relapse-free survival. We engineered prostate-specific

Indexed as

prostate cancerretroelementUXT

Identifiers

PMID30774773
PMCPMC6366831
OpenAlexW2914202640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.